WINDLAS1,135.00

Windlas Biotech Limited

· Pharma & Health
₹ CrorePeersHESTERBIOINDOCOSAIPARENTSYNCOMFPANACEABIONGLFINEHIKALJAGSNPHARMMcap ₹2,396 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Inventory Days (DIO)7,665.9912,759.951,811.64
Receivable Days (DSO)78.8380.1591.81
Payable Days (DPO)16,211.2526,220.586,988.60
Cash Conversion Cycle (days)-8,466.43-13,380.48-5,085.15
Working Capital Turnover2.432.762.96
Asset Turnover1.011.001.00
Cash Conversion (CFO/Net Income)1.871.121.58
CFO/EBITDA1.390.721.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.